Trials / Completed
CompletedNCT01757470
Vandetanib Risk Minimisation Effectiveness
Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Effectiveness of risk minimisation interventions for vandetanib in Canada
Detailed description
As part of the new drug approval process in Canada, AstraZeneca has committed to Health Canada to conduct a Drug Utilization Study among patients recently treated with CAPRELSA (vandetanib) and a Knowledge and Understanding Survey among the prescribing physicians to determine whether the product monograph, communication plan, and educational material developed by AstraZeneca Canada for vandetanib are adequate to provide knowledge about the potential risks associated with this product, and if other medications taken concomitantly with vandetanib are managed adequately.
Conditions
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2012-12-31
- Last updated
- 2016-08-31
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01757470. Inclusion in this directory is not an endorsement.